Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An <i>in Vitro</i> Study-Reference-Cited by-同舟云学术

Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study

Published:2016 Issue:8 Volume:39 Page:1238-1246
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Elsayed Mahitab¹,Kobayashi Daisuke¹,Kubota Toshio¹,Matsunaga Naoya²,Murata Ryusei¹,Yoshizawa Yuko¹,Watanabe Natsuki¹,Matsuura Tohru¹,Tsurudome Yuya³,Ogino Takashi³,Ohdo Shigehiro³,Shimazoe Takao¹

Affiliation:

1. Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University

2. Department of Glocal Health Care Science, Graduate School of Pharmaceutical Science, Kyushu University

3. Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/39/8/39_b15-00746/_pdf

Reference64 articles.

1. 1) Low SK, Kuchiba A, Zembutsu H, Saito A, Takahashi A, Kubo M, Daigo Y, Kamatani N, Chiku S, Totsuka H, Ohnami S, Hirose H, Shimada K, Okusaka T, Yoshida T, Nakamura Y, Sakamoto H. Genome-wide association study of pancreatic cancer in Japanese population. PLoS ONE, 5, e11824 (2010).

2. 2) Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat. Rev. Cancer, 2, 897–909 (2002).

3. 3) Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res., 57, 1731–1734 (1997).

4. 4) Khvalevsky EZ, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E. Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl. Acad. Sci. U.S.A., 110, 20723–20728 (2013).

5. 5) Walker K, Olson M. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev., 15, 62–68 (2005).

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zoledronic acid targets chemo-resistant polyploid giant cancer cells;Scientific Reports;2023-01-09

2. Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer;Scientific Reports;2022-11-14

3. Inhibition of Histamine Release from RBL-2H3 Cells by Zoledronate Did Not Affect Rab27a/Doc2a Interaction;Biological and Pharmaceutical Bulletin;2021-12-01

4. Bisphosphonate Use Does Not Impact Survival in Patients with Pancreatic Cancer: A Propensity Score Matching Analysis;Gut and Liver;2021-09-15

5. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer;Journal for ImmunoTherapy of Cancer;2021-07